GLP1R and metabolic dysfunction-associated steatohepatitis: Its approval for non-cirrhotic MASH with fibrosis not only broadens the clinical scope of GLP-1 receptor agonists but also marks a paradigm shift toward metabolic-targeted therapies in liver disease.